Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
Date:2/21/2008

NEW YORK, Feb. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, February 25, 2008 at 8:30 a.m. EST to discuss the fourth quarter and year-end 2007 financial results and business outlook for 2008. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-874-1565 (U.S.), 1-719-325-4750 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide) oral gelcaps, previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix ... it has completed a collaborative research program ... analytics.  Using Fast Collective Evolution Technology (FACET), ... including all measurements obtained from each of ... Phase 2 clinical trials ASSERT, SUSTAIN and ...
(Date:3/4/2015)... 04, 2015 Proove Biosciences ... Medicine, is excited to announce the launch of ... Optimize the Management of Pain”. , The continuing ... for the next year. The focus of the ... recognize inadequate pain treatments, integrate appropriate pain management ...
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... Aug. 7 Kensey Nash Corporation today announced an ... along with the trademark, inventory and other assets associated ... the terms of the agreement, the Company and Biomet ... agreement. Pursuant to the agreement, following a brief transition ...
... , , SAN MATEO, Calif., Aug. ... , , , Granted ... non-diabetic adults, either alone or in combination with other medicinal products for pain ... (Astellas) for commercialization of Qutenza in Europe, Middle East and Africa, including commercialization ...
... , , SAN MARINO, ... VRAL) has formed a wholly owned subsidiary called MetaCytoLytics, Inc. ... University of Colorado Professor M. Karen Newell called "metabolic disruption ... to generate energy from glucose or from fatty acids. ...
Cached Biology Technology:Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3NeurogesX Reports Second Quarter 2009 Results 2NeurogesX Reports Second Quarter 2009 Results 3NeurogesX Reports Second Quarter 2009 Results 4NeurogesX Reports Second Quarter 2009 Results 5NeurogesX Reports Second Quarter 2009 Results 6NeurogesX Reports Second Quarter 2009 Results 7NeurogesX Reports Second Quarter 2009 Results 8NeurogesX Reports Second Quarter 2009 Results 9NeurogesX Reports Second Quarter 2009 Results 10NeurogesX Reports Second Quarter 2009 Results 11NeurogesX Reports Second Quarter 2009 Results 12Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... at the Living Planet Symposium have been hearing about ... almost three months, the satellite is in excellent health ... presented at the symposium. Prof. Duncan Wingham, Lead ... in very good shape exceeding in-orbit specifications, the ...
... protein that helps pack DNA into the cell nucleus has ... researchers found that the protein, histone H1, also takes part ... all proteins are made. The study appeared online May ... A human cell,s genetic material is so vast that it ...
... of the extinction of woolly mammoths and other large mammals ... fallen victim to the same type of "trophic cascade" of ... the global decline of predators such as wolves, cougars, and ... originally begun by human disruption of ecosystems, a new study ...
Cached Biology News:CryoSat-2 exceeding expectations 2Histone H1 regulates gene activity throughout the cell cycle 2Histone H1 regulates gene activity throughout the cell cycle 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 2'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 4
... The Luminex 200 IS System is ideal ... Upstate's Beadlyte reagents. This system contains the ... developed by Luminex. The user can design ... kits. The system has fully integrated graphing ...
...
... Cell Lines stably express the regulatory ... line is functionally tested for induction ... expression control vector pGene/V5-His/lacZ and by ... with mifepristone (Figure 1). These cell ...
... Includes: Sufficient library for 10 separate ... independent sequences, -28 gIII Sequencing Primer ... -96 gIII Sequencing Primer (100 pmol), ... coli strain ER2738, Control target (Streptavidin) ...
Biology Products: